Siemens Healthineers will invest around $300 million in its Walpole, Mass. laboratory diagnostics manufacturing and research and development facility. The investment extends over four years and is another proof point that Siemens Healthineers invests in innovation to enable healthcare providers around the world to meet their current challenges and to excel in their respective environments.
Through products and solutions designed to increase efficiency and reduce costs, Siemens Healthineers sets new trends in healthcare together with its customers – working under the motto “Engineering Success. Pioneering Healthcare. Together.”
“The expansion of the Walpole facility fits into the strategic growth plans for the company and allows us to increase our manufacturing footprint in the United States, the largest healthcare market in the world,” said Bernd Montag, Chief Executive Officer, Siemens Healthineers.“The laboratory instruments and reagents developed and manufactured at the Siemens Healthineers Walpole facility impact patients and healthcare providers across the globe.”
The Walpole facility currently employs more than 700 employees and is the main manufacturing facility for assays that run on the ADVIA® Centaur family of immunoassay instruments, and for consumables for the company's molecular and blood gas testing instruments.
The facility will also manufacture assays to run on the immunoassay module of the AtellicaTM Solution, which is currently under FDA review. R&D efforts at the site bring new tests to the diagnostics market to help physicians diagnose and treat disease.
With a 37-year history of manufacturing products in Walpole, we saw an opportunity to leverage the local talent in the community to further our growth and expansion plans”
Franz Walt, President, Laboratory Diagnostics, Siemens Healthineers.
The company plans to upgrade and expand its existing 500,000 sq. ft. complex. Renovations to the existing facility will begin in the coming weeks. The expansion—which will include manufacturing, warehouse, office and lab space—is set to begin in the summer. Siemens Healthineers is committed to creating at least 400 positions.
The company anticipates that it may ultimately create up to as many as 700 new permanent jobs to bring the total employment at the site to between 1,300 and 1,600 by 2026. These employees will join the 46,000 Siemens Healthineers around the world who enable healthcare providers to deliver excellent patient care.
“I am proud that Siemens has chosen to grow its laboratory diagnostics unit in Massachusetts,” said Governor Charlie Baker.
“The Commonwealth is pleased to continue building a pro-growth economic environment that creates more jobs for our communities, and remains focused on supporting globally competitive life sciences and advanced manufacturing. I thank Siemens Healthineers for their commitment to Massachusetts, and look forward to continuing to partner with the company to move this important economic development project forward.”